Compare VTS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTS | GERN |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 742.9M | 808.3M |
| IPO Year | 2022 | N/A |
| Metric | VTS | GERN |
|---|---|---|
| Price | $16.05 | $1.36 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $2.17 |
| AVG Volume (30 Days) | 588.4K | ★ 12.5M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 11.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $273,989,000.00 | N/A |
| Revenue This Year | $5.48 | $26.91 |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.22 | N/A |
| 52 Week Low | $15.76 | $1.04 |
| 52 Week High | $27.15 | $2.01 |
| Indicator | VTS | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 35.15 | 61.20 |
| Support Level | N/A | $1.22 |
| Resistance Level | $20.13 | $1.46 |
| Average True Range (ATR) | 0.49 | 0.07 |
| MACD | -0.13 | 0.03 |
| Stochastic Oscillator | 11.65 | 93.10 |
Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana with limited operations. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.